ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: Volcano Corporation (VOLC) Report Updated: Sep 14, 2014 | Print This Page

Get more stock ratings by Louis Navellier

Volcano Corporation (VOLC)

Rating: Strong Sell Volatility: Moderate
Total Grade: F Industry: Health Care Equipment & Supplies
Competitors: ERB, BABY, ZLTQ, SNN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: F down no change
Last Week: F same no change
Two Weeks Ago: F up no change
service keys

Volcano Corporation© quotemedia

Company Profile

Volcano Corporation designs, develops, manufactures, and commercializes intravascular ultrasound (IVUS) and fractional flow reserve (FFR) products used in the diagnosis and treatment of vascular and structural heart disease. It offers multi-modality consoles, which are marketed as stand-alone units that can be integrated into hospital-based interventional surgical suites, such as catheterization laboratories. The company provides IVUS products, including single-procedure disposable phased array and rotational IVUS imaging catheters; and additional functionality options comprising virtual histology tissue characterization, and ChromaFlo stent apposition analysis. It also offers FFR products, such as pressure and flow consoles, and single-procedure disposable pressure and flow guide wires used to measure the pressure and flow characteristics of blood around plaque enabling physicians to gauge the plaque’s physiological impact on blood flow and pressure. In addition, the company develops and manufactures optical monitors for the telecommunication industry; laser and non-laser light sources; optical engines used in the medical OCT imaging systems and advanced photonic components; and sub-systems used in spectroscopy and other industrial applications. Its products under development include image-guided therapy device and micro and thrombectomy catheters. The company’s ongoing clinical studies comprise assessment of dual anti-platelet therapy with drug-eluting stents; vascular evaluation for revascularization; fractional flow reserve and intravascular ultrasound relationship study; adensonine vasodilation independent stenosis evaluation; and evaluation of XIENCE PRIME. It sells its products through direct sales force and distributors, as well as through third parties supply and distribution agreements primarily in the United States, Japan, Europe, the Middle East, Africa, and internationally. The company was founded in 2000 and is headquartered in San Diego, California.

Recent News: Volcano Corporation